Trial · NCT05708677
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Wound Closure | 5 years | Proportion of RDEB wounds with healing ≥50%, ≥75%, and 100% at all clinic visits up to Month 54 as determined by direct investigator assessment. |
| Primary | Pain Severity Scale (Wong-Baker FACES) | 5 years | Change in pain assessed by Wong-Baker FACES scale at all clinic visits up to Month 54. The minimum score value is 0 and the maximum score value is 10, with the higher scores being the worse outcome. |
| Primary | Itch Severity Scale | 5 years | Longitudinal change of Itch severity scores assessed at all clinic visits up to Week 54. The minimum score value is 0 and the maximum score value is 10, with the higher scores being the worse outcome. |
| Primary | Zarit Burden Interview Scale | 5 years | Longitudinal change of Zarit Burden Interview Short Form (ZBI-12) for caregiver scores related to wound care, assessed at all clinic visits up to Month 54. The minimum score value is 0 and the maximum score value is 4, with the higher scores being the worse outcome. |
| Primary | Quality of Life in Epidermolysis Bullosa | 5 years | Quality of Life in Epidermolysis Bullosa (QOLEB) responses will be assessed at all clinic visits up to Month 54. |
| Primary | Caregiver Global Impression of Change for Pain Scale | 5 years | Caregiver Global Impression of Change for Pain (CrGI-Pain) scores assessed at all clinic visits up to Month 54. The minimum score value is 1 and the maximum score value is 7, with the higher scores being the worse outcome. |
| Primary | Wound Infection and Adverse Events | 5 years | The number of participants and wounds that have an infection or any related adverse event. |
| Primary | The number of treatment-emergent adverse events. | 5 years | The number of treatment-emergent adverse events. |
| Primary | Serious Adverse Events | 5 years | The number of participants and wounds that result in hospitalization (serious adverse event \[SAE\]). |
| Primary | Incidence of squamous cell carcinoma. | 5 years | Incidence of squamous cell carcinoma. |
| Primary | Replication-competent retrovirus (RCR) status | 5 years | Replication-competent retrovirus (RCR) status |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05708677/registered